Invitae’s genetic testing and patient engagement programs remove barriers to diagnosis and bring new therapies to market sooner
Invitae has partnered with biopharmaceutical companies and advocacy organizations to develop novel programs to address challenges in the diagnostic journey. These programs play a pivotal role in the diagnosis and management of rare disease by removing barriers to genetic testing and making patients and their clinicians aware of clinical trials and research that bring new treatments to market.
The abstract details the Behind the Seizure program with BioMarin Pharmaceutical in pediatric epilepsy and the Mast Cell Connect patient registry with Blueprint Medicines in mastocytosis.
To learn more about Invitae, visit the website.